KURA ONCOLOGY, INC. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
KURA ONCOLOGY, INC. (KURA) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $328.00 million as of 2022-06-30, per its 10-Q filed 2022-08-03.
Discontinued › Notes › Investments › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2022-08-03
- 2022-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $328.00M.
- 2022-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $366.80M.
- 2021-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $373.90M.
- 2021-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $200.20M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2022-06-30 | $328.00M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $366.80M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $373.90M 10-K · filed 2022-02-24 |
| 2021-09-30 | $200.20M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $200.30M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $149.50M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $85.20M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |